Skip to main content
ALT
NASDAQ Life Sciences

Pemvidutide Cuts Heavy Drinking Days in Phase 2 AUD Trial; FDA Meeting Set for December

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.135
Mkt Cap
$415.295M
52W Low
$1.91
52W High
$6.44
52W Position info
12% above low
Off High info
67% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ALT is trading near its 52-week low of $1.91 (12% above the low).

Summary

Altimmune presented full RECLAIM Phase 2 data in alcohol use disorder at AASLD, showing pemvidutide cut heavy drinking days per week by 4.20 versus 2.75 for placebo (p=0.0014), with 42.2% of treated patients reaching zero heavy drinking days versus 17.4% on placebo. The PEth biomarker fell 153.4 ng/mL on drug while rising 22.0 ng/mL on placebo, and patients lost 8.7% of body weight versus a 0.4% gain. Tolerability was manageable: GI side effects were mostly mild-to-moderate and discontinuation rates were comparable (20% vs 22%). The company will hold an End-of-Phase 2 meeting with the FDA in December to design the Phase 3 registrational AUD program, the key near-term step for this indication. This adds detail to the positive topline announced in July 2026 and comes alongside the ongoing Phase 3 PERFORMA MASH trial and the fully enrolled RESTORE ALD study.

At the time of this announcement, ALT was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.3M. The 52-week trading range was $1.91 to $6.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ALT - Latest Insights

ALT
Aug 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $2.12 info
Change: -$0.8434 (-28%) info
Market Cap: $411.736M info
ALT
Aug 12, 2026, 7:43 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $2.12 info
Change: -$0.9433 (-31%) info
Market Cap: $411.736M info
ALT
Aug 12, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.01
Real-time Price: $2.12 info
Change: -$0.8933 (-30%) info
Market Cap: $411.736M info
ALT
Jul 28, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.44
Real-time Price: $2.12 info
Change: -$1.32 (-38%) info
Market Cap: $411.736M info
ALT
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.96
Real-time Price: $2.12 info
Change: -$0.8433 (-28%) info
Market Cap: $411.736M info